Empowered Funds’s Gilead Sciences GILD Stock Holding History

Empowered Funds’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,151	Closed	-$442K	–	592
2022 Q4	$442K	Buy	+5,151	New	+$408K	0.03%	366

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Empowered Funds's GILD Position: Q2 2026 in Review

Empowered Funds increased its Gilead Sciences (GILD) stake by 16% in Q2 2026, buying an estimated $4M and bringing the position to 225,845 shares worth $28.5M. The position accounts for 0.15% of the portfolio, ranked #130.

Empowered Funds first reported a position in GILD in Q1 2017 and has held it in 29 quarters since. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Empowered Funds held 225,845 shares of Gilead Sciences worth $28.5M as of Q2 2026.
Empowered Funds bought 30,382 Gilead Sciences shares in Q2 2026, an estimated $4M.
Gilead Sciences made up 0.15% of Empowered Funds's portfolio in Q2 2026, its #130 holding.
Empowered Funds first reported a position in Gilead Sciences in Q1 2017 and has held it in 29 quarters since.
2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.